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ABSTRACT
Objectives To establish the role and effect of 
glucocorticoids and the endogenous annexin A1 (AnxA1) 
pathway in inß ammatory arthritis.
Methods Ankle joint mRNA and protein expression 
of AnxA1 and its receptors were analysed in 
naive and arthritic mice by real-time PCR and 
immunohistochemistry. Inß ammatory arthritis was 
induced with the K/BxN arthritogenic serum in AnxA1+/+ 
and AnxA1−/− mice; in some experiments, animals 
were treated with dexamethasone (Dex) or with human 
recombinant AnxA1 or a protease-resistant mutant 
(termed SuperAnxA1). Readouts were arthritic score, 
disease incidence, paw oedema and histopathology, 
together with pro-inß ammatory gene expression.
Results All elements of the AnxA1 pathway could 
be detected in naive joints, with augmentation during 
ongoing disease, due to the inÞ ltration of immune cells. 
No difference in arthritis intensity of proÞ le could be 
observed between AnxA1+/+ and AnxA1−/− mice. 
Treatment of mice with Dex (10 µg intraperitoneally daily 
from day 2) afforded potent antiarthritic effects highly 
attenuated in the knockouts: macroscopic changes 
were mirrored by histopathological Þ ndings and pro-
inß ammatory gene (eg, Nos2) expression. Presence of 
proteinase 3 mRNA in the arthritic joints led the authors 
to test AnxA1 and the mutant SuperAnxA1 (1 µg 
intraperitoneally daily in both cases from day 2), with the 
latter one being able to accelerate the resolving phase of 
the disease.
Conclusion AnxA1 is an endogenous determinant for 
the therapeutic efÞ cacy of Dex in inß ammatory arthritis. 
Such an effect can be partially mimicked by application of 
SuperAnxA1 which may represent the starting point for 
novel antiarthritic therapeutic strategies.
INTRODUCTION
There is genuine interest in detailing cellular and 
molecular events regulating the phase of the reso-
lution of inﬂ ammation, with the characterisation 
of speciﬁ c players and targets.1 This interest stems 
from the appreciation that, in ideal settings, a 
strong pro-inﬂ ammatory response, orchestrated by 
cytokines, adhesion molecules and chemoattract-
ants2 must be followed by an anti-inﬂ ammatory 
and pro-resolving phase, which assures spatial and 
timely control of the response the host organises 
upon encounter with an insult,3 leading to resolu-
tion and regain of tissue functions.
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Annexin A1 (AnxA1) is an effector of resolution.4
Highly expressed in immune cells (eg, polymorpho-
nuclear cells and macrophages), this protein is exter-
nalised to exert paracrine and juxtacrine effects, the 
vast majority of which are mediated by the formyl-
peptide receptor type 2 (FPR2/ALX ([Lipoxin A4 
receptor]) or FPR2, in rodents).5 Intriguingly, FPR2/
ALX is also the lipoxin A4 receptor
6 indicating the 
existence of important – yet not fully appreci-
ated – networks in resolution.7 Another receptor 
is also advocated to mediate the effects of AnxA1, 
the formyl-peptide receptor type 1 or FPR1 (FPR1 
in rodents),8 though it is unclear if and how this 
receptor binds the full-length protein9 or whether 
– more selectively – it would mediate effects of the 
AnxA1 peptidomimetic peptide Ac2-26.10
The majority of experimental approaches used 
to deﬁ ne properties of pro-resolving mediators 
have been reliant on models of acute inﬂ ammation, 
characterised by rapid polymorphonuclear inﬂ ux 
followed by inﬂ ammatory monocytes which differ-
entiate into tissue macrophages3 11 to phagocytose 
debris and apoptotic cells and favour tissue repair, 
a conclusive act in resolution that may require re-
epitheliation12 or a shift in ﬁ broblast phenotype.13
In this context, the pro-resolving nature of AnxA1 
has been demonstrated in a variety of experimental 
settings, noting induction of apoptosis, promotion 
of efferocytosis and tissue repair, spanning from 
models of acute inﬂ ammation (eg, 14 15) to a model 
of colitis where delayed resolution was observed 
in AnxA1−/− mice.16 An important aspect of AnxA1 
biology is its second messenger role in the actions 
of glucocorticoids, a function mainly addressed in 
cellular settings (eg, 17) or in models of acute inﬂ am-
mation.18 19 However, Yang’s group applied anti-
gen-induced arthritis to observe reduction afforded 
by dexamethasone (Dex) on synovitis, soft tissue 
inﬂ ammation and cartilage erosion attenuated in 
AnxA1−/− mice.20
The K/BxN serum-induced model of inﬂ amma-
tory arthritis is ideal for investigating the impact of 
speciﬁ c pro-resolving pathways. Using this model 
of active phase of rheumatoid arthritis, Krönke et 
al reported a higher degree of joint inﬂ ammation 
in 12/15-lipoxygenase−/− mice, associated with 
their inability to synthesise lipoxin A4.
21 Similarly, 
animals nulliﬁ ed for pro-resolving melanocor-
tin receptor type 3 displayed higher degree of 
arthritis and delayed resolution, accompanied by 
augmented cytokine expression and osteoclast 
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responsiveness.22 An equally interesting study investigated 
the effect of absence of glucocorticoid signal in osteoblasts, by 
means of restricted transgenic expression of 11β-hydroxysteroid 
dehydrogenase type 2, in this model of inﬂ ammatory arthritis. 
The outcome was that of a more attenuated arthritis in the 
transgenic mice when assessed macroscopically and histologi-
cally, and selectively in the delayed phase, after peak disease.23
The present study made use of the serum-induced model of 
inﬂ ammatory arthritis to: (1) monitor potential modulation of 
endogenous AnxA1, FPR1 and FPR2; (2) determine the effect of 
Dex in wild type and AnxA1−/− mice; and (3) establish the phar-
macological potential of exogenously administered AnxA1.
MATERIALS AND METHODS
Animals
BALB/c male 8-week old wild type AnxA1+/+ and AnxA1−/− 
mice24 were bred at Charles River (Kent, UK). All experiments 
were approved and performed under the guidelines of the Ethical 
Committee for the Use of Animals, Barts and The London School 
of Medicine and Home Ofﬁ ce regulations (Scientiﬁ c Procedures 
Act, 1986).
Model of inß ammatory arthritis
Arthritis induction
Mice received either 50+50 μl (day 0 and 2) or 200 μl (day 0) of 
arthritogenic K/BxN serum.22 Disease was monitored by assess-
ing the clinical score where a maximum of 12 points could be 
given per animal: 0 point, no evidence of inﬂ ammation; 1 point, 
subtle inﬂ ammation on metatarsal phalanges joints, individual 
phalanx; 2 points, swelling on dorsal or ventral surface of paw; 
3 points, major swelling on all aspects of paw.25 Paw volume was 
assessed by water plethysmometry (Ugo Basile, Milan, Italy).
Pharmacological intervention
Mice were injected intraperitoneally with Dex (disodium salt; 
Sigma, Dorset, UK) prepared in sterile phosphate buffered saline 
(Sigma) and given at a dose range of 3–30 μg once daily after 
disease onset (from day 2). AnxA1 and SuperAnxA1 were gener-
ated as recently described26 and administered intraperitoneally, 
from day 2, at 1 μg per mouse.26
Histology and immunohistochemistry
Histology
Joints were decalciﬁ ed and parafﬁ n embedded. Sections 
(4 micrometers) were stained with H&E or safraninO with 
fast green counterstain. Standard light microscopy was used to 
determine the degree of synovitis, pannus formation, cartilage 
and bone erosion which were graded from 0 (no disease) to 
5 (severe) by two blinded examiners, as reported.22
Immunohistochemistry
An antigen retrieval step using citrate buffer (pH 6.0) was per-
formed and then sections were incubated with rabbit polyclonal 
anti-AnxA1 (1:1000) (Zymed Laboratories, Cambridge, UK) or 
anti-FPR2 (1:4000).27 After washing and the secondary biotinylated 
antibody (Dako, Cambridge, UK), staining was detected using a 
peroxidase conjugated streptavidin complex (Dako) and colour 
developed using 3,3’ Diaminobenzidine (DAB) substrate (Sigma).
Molecular analyses
Ankle joints were snap frozen in liquid nitrogen and homog-
enised in Qiagen RLT plus buffer (Qiagen, Crawley, UK) using 
Precellys24 ceramic bead homogenisation technology (Bertin 
Technologies, Montigny-le-Bretonneux, France). RNA was 
extracted using RNeasy Plus mini kit (Qiagen) and genomic DNA 
contamination eliminated with Turbo DNA-free kit (Applied 
Biosystems, Foster City, California, USA). Complementary 
DNA was synthesised using SuperScriptIII reverse transcriptase 
and OligoDt primers (Invitrogen). Quantitative real-time PCR 
was performed using QuantiTect primers (Qiagen) and ABI 
Prism 7900 sequence detector system (Applied Biosystems). RQ 
values were calculated using the 2−( ΔΔCt) method and normal-
ised to an individual naive AnxA1+/+ or AnxA1−/− mouse (cali-
brator sample).
All Ct values were normalised to endogenous Gapdh gene 
product. Since factors such as hypoxia can inﬂ uence Gapdh gene 
levels,28 a second house-keeping gene Rpl32 was used to nor-
malise and conﬁ rm data (see table S2).
Statistics
Data are expressed as mean±SE. Student t test was used to compare
two groups. Comparison of clinical scores and paw volumes 
were made using 2-way analysis of variance. A value of p<0.05 
was considered signiﬁ cant.
RESULTS
Characterisation of joint inß ammation
We began this study to optimise the model by comparing two 
different protocols: 200 μl of serum at day 0 (as in22) or 50+50 
μl at day 0 and day 2. A remarkably similar arthritic response 
could be measured with respect to disease proﬁ le and intensity 
(ﬁ gure 1A). High levels of disease were achieved as early as day 
2 postinjection with maximal response by day 6, after which 
the disease resolved to almost normal by day 20. Incidence of 
disease was similar between the two volumes of K/BxN serum 
(table S1). The arthritic response was mirrored by changes in 
paw volume with similar proﬁ les with no difference between 
the two protocols (ﬁ gure 1B).
Microscopic analyses of non-arthritic ankle joints showed an 
acellular articular cavity with intact unicellular synovial lining 
and uniform cartilage structure (ﬁ gure 1C, top panel). In con-
trast, arthritic joints from both 50+50 μl and 200 μl K/BxN arthri-
tis groups displayed marked cell inﬁ ltration within a thickened 
synovial lining. Pannus invasion leading to cartilage erosion was 
observed and proteoglycan loss was conﬁ rmed with safraninO 
(ﬁ gure 1C, middle and bottom panels). Quantitative histologi-
cal scoring showed no signiﬁ cant difference between the two 
groups of arthritic mice (ﬁ gure 1D).
The ankle is the predominant joint to be affected in this model 
of inﬂ ammatory arthritis, yet we monitored structural changes 
in the knee, as is perhaps more relevant to human disease; 
we observed that knee joints displayed mild synovitis 
accompanied with thickening of synovial lining, pannus 
formation and marked cartilage erosion (see ﬁ gure S1). Based 
on these results, in agreement with a recent published study,29 
the 50+50 μl serum protocol was selected for subsequent 
experimentation.
Expression of AnxA1 and FPR2 in the joint
At the mRNA level, a low degree of expression for both FPR1 
and FPR2 could be measured, with high AnxA1 message content 
(see table S2). These results were partially conﬁ rmed by pro-
tein analyses, since AnxA1 was mildly expressed and localised 
predominantly in the synovial lining, while FPR2 was localised 
to the periosteal lining with very little detection in synovium 
(ﬁ gure 2A). In arthritic joints, AnxA1 and FPR2 expression was 
3
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highly detectable within the synovial lining (FPR2) and tissue 
(AnxA1 and FPR2) (ﬁ gure 2B). Antibody controls and AnxA1−/−
joints did not show any staining (ﬁ gure 2C,D).
Dex is inactive in AnxA1−/− mice
Despite wide application of this model of inﬂ ammatory 
arthritis, the bioactions of glucocorticoids have been scantly 
investigated. We selected the 10-μg dose of Dex from initial 
studies (ﬁ gure S2). Administration of Dex to AnxA1+/+ mice 
exerted profound inhibitory effects with ~60% inhibition of 
the severity of arthritis at day 6 and ~80% at day 10 compared 
with vehicle-treated mice (ﬁ gure 3A). AnxA1−/− mice displayed 
a similar proﬁ le of arthritis to AnxA1+/+ animals. However, 
the antiarthritic effect of Dex was absent in animals nulliﬁ ed 
for AnxA1 (ﬁ gure 3A). Analysis of presence of severe disease 
(score ≥8) indicated a trend for higher incidence in AnxA1−/−
mice and a marked reliance on endogenous AnxA1 for the 
protective effects of Dex (table S3).
Histological analyses were in line with arthritic scores. 
AnxA1+/+ mice displayed marked synovitis accompanied by 
pannus formation and cartilage destruction (ﬁ gure 3B, left 
panels). Treatment with Dex prevented signs of disease 
(ﬁ gure 3B, middle panels), while AnxA1−/− mice treated with 
vehicle control (not shown) and Dex (ﬁ gure 3B, right panels) 
showed similar disease pathology to AnxA1+/+ mice. These 
structural changes were reﬂ ected in the histological scores 
with ~75% inhibition afforded by Dex only in AnxA1+/+ mice 
(ﬁ gure 3C).
Figure 1 Characterisation of the arthritic response to low volume K/BxN serum. Mice (n=8) were given an intraperitoneal injection of 50 μl at day 0 
and day 2 (50+50 μl) or a single injection of 200 μl at day 0 of K/BxN serum. (A) Arthritic scores and (B) paw oedema were monitored over the time 
course. No signiÞ cant difference (two-way analysis of variance) was observed between the two K/BxN serum groups. (C) Ankles of naive, 50+50 
μl and 200 μl K/BxN serum group. DecalciÞ ed parafÞ n embedded joints were stained by H&E and safraninO. Representative images are shown; scale 
bars, 50 μm. CE, cartilage erosion; PF, pannus formation; S, synovitis. (D) Histomorphometric analyses of joint sections. All results are expressed as 
mean±SE.
annrheumdis-2011-201180.indd   3 9/8/2012   2:00:35 PM
1874 Ann Rheum Dis 2012;71:1872–1880. doi:10.1136/annrheumdis-2011-201180
Basic and translational research
Analyses of inﬂ ammatory gene messages, normalised to 
Gapdh and Rpl32 (see ﬁ gure S3) and selected from our previous 
study,22 revealed that in wild type mice Dex inhibited Cxcl10, 
Nos2, interleukin (IL)-1β and Ccl2. Tumour necrosis factor α 
(TNFα) was inhibited by ~25% while expression of the chem-
okine receptor Cxcr3 was not modulated (ﬁ gure 3D). These 
inhibitory effects of Dex were absent or signiﬁ cantly reduced 
in AnxA1−/− mice.
Next, we monitored expression of AnxA1 and its receptors, nor-
malised to Gapdh and Rpl32 (see ﬁ gure S4). In arthritic AnxA1+/+ 
mice, both FPR1 and FPR2 mRNA expression was enhanced over 
naive joints (ﬁ gure 4), a ﬁ nding which is in line with FPR2 protein 
expression (see ﬁ gure 2). Dex decreased both FPR1 and FPR2 mes-
sage with little comparative effect on AnxA1 (ﬁ gure 4). In mice 
devoid of AnxA1, a >10-fold increase in FPR1 expression was 
observed comparing arthritic to naive joints, with FPR2 remaining 
Figure 2 Protein expression of AnxA1 and FPR2 in ankle joints of naive mice. Ankles of naive and K/BxN serum (50+50 μl, day 0 and day 2) were 
processed (see methods) and stained for AnxA1 and FPR2, with a haematoxylin counterstain. Images representative of three distinct analyses in 
four mice per status are shown. (A) Naive mouse ankle joints. (B) Serum-treated mouse ankle joint. (C) Same joints but tested without the primary 
antibody. (D) Joint of an AnxA1−/− mouse acting as negative control for AnxA1 staining. Scale bars, 20 μm.
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at a similar expression. In absence of AnxA1, Dex could not regu-
late either FPR1 or FPR2 gene expression (ﬁ gure 4).
SuperAnxA1 accelerates resolution of the arthritic joint
In the ﬁ nal set of experiments, we assessed the pharmacologi-
cal potential of these ﬁ ndings. Proteinase 3 (PR3) may limit 
AnxA1 functions in neutrophilic inﬂ ammation, cleaving it at the 
N-terminal region. Thus, we monitored the proﬁ le of PR3 gene 
in the arthritic joint and found it signiﬁ cantly rose from baseline 
(day 0) to peak of disease (day 6) (ﬁ gure 5 and ﬁ gure S5). This 
observation, coupled with abundant expression of FPR1 and 
FPR2 in the joints justiﬁ ed the testing of SuperAnxA1. Dosed at 
1 μg per mouse, AnxA1 was not particularly effective in reduc-
ing disease (ﬁ gure 5B). On the other hand, cleavage-resistant 
SuperAnxA1 did not affect disease progress (eg, from day 2 to 
day 6) but signiﬁ cantly accelerated resolution (ﬁ gure 5B), with 
50% less disease incidence compared with controls (table 1).
The macroscopic joint protection afforded by SuperAnxA1 
was conﬁ rmed microscopically, with preservation of cartilage 
structure with little loss of proteoglycans (ﬁ gure 5C, middle 
Figure 3 Dexamethasone (Dex) attenuates K/BxN arthritis in AnxA1+/+ but not AnxA1−/− mice. AnxA1+/+ and AnxA1−/− mice were given an 
intraperitoneal injection of K/BxN serum (50 μl at day 0 and day 2) and then received vehicle or Dex (10 µg intraperitoneally daily). (A) Arthritic scores 
as monitored over a 10-day time course. *p<0.05 versus appropriate vehicle control (two-way analysis of variance). (B) Right ankles of mice from 
each experimental group were taken at day 10 and joints processed for staining by H&E and safraninO. Representative images are shown. Scale 
bars, 50 μm. CE, cartilage erosion; PF, pannus formation; S, synovitis. (C) Histomorphometric analyses of joint sections. *p<0.05 versus appropriate 
vehicle control (Student t test). (D) Quantitative real-time PCR was performed on cDNA from left ankle joints; pro-inß ammatory genes were analysed 
with all Ct values normalised to endogenous Gapdh (four mice per group). RQ values were calculated using 2−(ΔΔCt) and data shown here as mean 
% gene inhibition by Dex relative to vehicle control groups±SE. Naive joints were set as the calibrator samples. *p<0.05 versus respective vehicle 
control (Student t test).
annrheumdis-2011-201180.indd   5 9/8/2012   2:00:48 PM
1876 Ann Rheum Dis 2012;71:1872–1880. doi:10.1136/annrheumdis-2011-201180
Basic and translational research
panels). Synovitis was apparent within these joints, but substan-
tially lower than controls (ﬁ gure 5C, top panels). The joints of 
AnxA1 treated mice were disrupted to a similar extent as con-
trols (ﬁ gure 5C, bottom panels). Quantitative analysis of dam-
age within the ankle joints conﬁ rmed the observational studies 
(ﬁ gure 5D). Finally, ankle joints from vehicle- and SuperAnxA1-
treated mice demonstrated reduced expression of the Cxcl10 
and Cxcr3 pair, as well as Nos2, IL-1β, Ccl2, IL-6 but not IL-10 
and TNFα (ﬁ gure S6).
DISCUSSION
AnxA1 is the prototype of a new class of mediators able to 
potently modulate both the innate and adaptive immune 
response; while effecting inhibitory properties on inﬂ ammatory 
cells, setting in motion pro-resolving responses, this protein acts 
as a positive relay in T cell activation.4 As an example, exog-
enous and endogenous AnxA1 potentiate T cell receptor-down-
stream signalling30 and assure proper dendritic cell-mediated T 
cell clonal expansion.31 In agreement with these dual functions, 
AnxA1−/− mice experience augmented acute inﬂ ammatory 
responses,14 15 yet display reduced degree of tissue damage in an 
experimental model of multiple sclerosis.32 Less clear is the role 
of the protein in models of arthritis.
In the collagen-induced arthritis model, AnxA1 injection during 
the immune phase (within 1 week postcollagen immunisation) 
led to higher disease as emerged 3 weeks later.30 In a model of 
antigen-induced arthritis, assessed at a single time-point (day 7),
endogenous AnxA1 modulated some of the anti-inﬂ ammatory 
effects of Dex, including inhibition of pro-inﬂ ammatory genes 
including IL-1β and TNFα.20 No studies have yet investigated 
the role of endogenous or exogenous AnxA1 in the serum-
induced inﬂ ammatory arthritis model.
K/BxN serum-induced arthritis33 34 is a versatile model that can 
be applied to transgenic mice with little dependence on strain.35 
This model addresses the contribution of neutrophils and mac-
rophages to inﬂ ammatory arthritis, as evident from depletion 
studies.36 37 Conversely, this experimental arthritis does not 
rely on T and B cells as demonstrated with the RAG1−/− mice28 
which, in contrast, display delayed disease onset and severity 
in collagen-induced arthritis.38 Here we describe that low dos-
age arthritogenic serum provokes a high degree of arthritis and 
disease incidence, data which are in agreement with a recent 
study by Boilard’s group.29 We noted a remarkable joint disrup-
tion and report a novel parallelism between the ankle and knee 
joint. Marked synovitis associated with disruption of cartilage 
occurs along a well-deﬁ ned time-proﬁ le with peak disease at 
day 6 followed by a resolution phase.22 35 Use of transgenic 
mice has allowed some deﬁ nition of the disease pathogenesis, 
revealing a fundamental role for myeloid cells36 37 and IL-1.39 40 
More recently, this model of arthritis has been applied to pro-
resolving pathways, noting that 12/15-lipoxygenase or melano-
cortin type-3 receptor deﬁ cient mice experience a higher degree 
of disease.21 22
AnxA1 is highly abundant in myeloid and stromal cells and its 
expression can be modulated by glucocorticoids and other anti-
inﬂ ammatory drugs.41 In addition, cell activation such as adhe-
sion or extravasation also engages the AnxA1 system as a way 
to activate an inhibitory circuit to modulate the inﬂ ammatory 
response.27 After several pharmacological investigations with 
AnxA1 or mimetics, AnxA1 null mice were produced and tested 
in models of acute inﬂ ammation15 24 revealing important modu-
latory functions.4 As discussed above, AnxA1 role in chronic 
inﬂ ammatory settings in less deﬁ ned.
This study began by detecting protein and mRNA of elements 
of the AnxA1 pathway during ongoing inﬂ ammatory arthritis, 
reporting a high degree of expression for AnxA1, FPR1 and 
FPR2 both in resting and arthritic joints. At the protein level, 
AnxA1 localisation in the mouse synovium seems to parallel 
that observed in the human rheumatoid arthritis synovium.42 
However, at least in the conditions applied here, lack of AnxA1 
does not seem to impact on the proﬁ le of disease. Yet, it remains 
to be seen whether such a lack of function would also be seen 
in knockouts for the AnxA1 receptors.5 43 As an example, in pre-
liminary observations, mice nulliﬁ ed for FPR2 displayed higher 
arthritic score upon injection of the arthritogenic serum.44
Glucocorticoids have been scarcely tested in this model. 
Buttgereit et al have tested the effect of osteoblast-restricted 
absence of glucocorticoid signalling on disease outcome, not-
ing a worsening with marked joint disruption.23 In these mice, 
bone cells could not respond to glucocorticoids from birth; thus, 
it is possible that developmental aspects might be relevant and 
subtle long-term alterations occur. For instance, it is known that 
glucocorticoids exert a permissive effect on important cytokine 
function in the liver, by assuring proper expression of the IL-6 
and IL-1 receptors.45 46 IL-6 is also a master-cytokine for oste-
oblasts (and ﬁ broblasts) and so a malfunctioning or inadequate 
glucocorticoid signalling, prolonged from birth, may generate 
responses that are not necessarily replicated by acute glucocor-
ticoid treatment.
In keeping with this, our pharmacological analyses with 
doses of Dex as low as 10 μg exerted potent protective effects 
on the joint, evident both as inhibition of pannus formation and 
chondro-protection. It was striking to observe that the effects of 
the glucocorticoid were lost in AnxA1−/− animals. Thus, while 
AnxA1−/− mice did not experience a difference in the extent and 
proﬁ le of arthritis, at variance from the antigen-induced arthritis 
model,20 endogenous AnxA1 still proved important in the inhib-
itory effects of Dex on a discrete set of pro-inﬂ ammatory genes, 
of which IL-1β, Cxcl10 and Ccl2 were of particular interest. 
Selective modulation of gene expression downstream AnxA1 is 
in keeping with the observations made in the antigen-induced 
Figure 4 ProÞ le of AnxA1, FPR1 and FPR2 gene product expression 
in ankle joints of AnxA1+/+ and AnxA1−/− mice treated with 
dexamethasone (Dex). AnxA1+/+ and AnxA1−/− mice were given an 
intraperitoneal injection of K/BxN serum (50 μl at day 0 and day 2) and 
then received vehicle or Dex (10 µg intraperitoneally daily). Quantitative 
real-time PCR was performed on cDNA from left ankle joints of mice 
from each experimental group (day 10). The AnxA1, FPR1 and FPR2 
genes were analysed with all Ct values normalised to endogenous 
Gapdh (four mice per group). Naive joints were set as the calibrator 
samples. Mean RQ values±SE shown here were calculated using 
2−(ΔΔCt) method. *p<0.05 versus naive; ¤p<0.05 versus appropriate 
vehicle control; #p<0.05 versus AnxA1+/+ group (Student t test).
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arthritis model.20 The fundamental role that IL-1β exerts in this 
model of inﬂ ammatory arthritis has been addressed through a 
variety of genetic approaches targeting directly the cytokine, its 
receptor39 47 or endogenous antagonist.40
Modulation of gene expression downstream of endogenous 
AnxA1 can also be discussed in relation to the modulation of 
genes of the AnxA1 pathway. In fact, Dex did not appear to 
induce AnxA1 or FPR gene expression at the level of the joint, 
yet was highly reliant on endogenous AnxA1 both with respect 
to cell recruitment and inﬂ ammatory gene expression. We rea-
son that these data indicate multiple functions of endogenous 
AnxA1, which become of relevance only after administration of 
the glucocorticoid.
The lack of correlation between AnxA1 gene product and pro-
tein is intriguing though it should be said that glucocorticoid-
regulation of the AnxA1 pathway is multifaceted; thus, non-
genomic modulation48 with release of the protein, for instance, 
could account for apparent lower tissue levels of the AnxA1 
protein. AnxA1 analysis, at a single time point, could also be con-
founded by genomic regulation exerted by glucocorticoids15 49
Table 1 SuperAnxA1 reduces the severity of inß ammatory arthritis
Time (days) Vehicle control SuperAnxA1 AnxA1
 0   0% (0/6)  0% (0/6)   0% (0/6)
 6 100% (6/6) 83.3% (5/6) 100% (6/6)
10 100% (6/6) 50% (3/6) 100% (6/6)
Data report the number of mice with a severe arthritic score taking a threshold of ≥8. 
SuperAnxA1 or AnxA1 was given from day 2 at daily doses of 1 µg intraperitoneally; 
the K/BxN arthritogenic serum was given on day 0 and day 2 at volumes of 50 µl each 
time.
Figure 5 SuperAnxA1 accelerates resolution of K/BxN arthritis. AnxA1+/+ mice (n=6) were given an intraperitoneal injection of K/BxN serum (50 
μl at day 0 and day 2) and then received vehicle, human recombinant AnxA1 or SuperAnxA1 (1 µg intraperitoneally daily from day 2). (A) PR3 gene 
product expression was analysed with Ct values normalised to endogenous Gapdh. RQ values were calculated using 2−(ΔΔCt) and data shown 
here as mean±SE. Naive mice (D0) were set as the calibrator samples. *p<0.05 versus naive (Student t test). (B) Arthritic score. *p<0.05 versus 
vehicle control (two-way analysis of variance). (C) Right ankles of mice from each experimental group were taken at day 10 and joints processed for 
staining by H&E and safraninO. Representative images are shown. Scale bars, 50 μm. CE, cartilage erosion; PF, pannus formation; S, synovitis. (D) 
Histomorphometric analyses of joint sections. *p<0.05 versus vehicle control (Student t test).
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and other factors present in an inﬂ amed joint such as IL-650 
and TNF.51 Clearly, the current lack of characterisation of the 
AnxA1 promoter contributes to this poor understanding of the 
mechanisms operative in these settings. Moreover, the fact that 
glucocorticoids like Dex induce AnxA1 gene in innate immune 
cells14 15 while downregulating it in adaptive immune cells52 
adds another layer of complexity to this issue which inevitably 
requires further experimentation.
The versatility of this model of inﬂ ammatory arthritis justi-
ﬁ es its application to a variety of targets; in line with the major 
inﬁ ltration of neutrophils and mast cells,53 we could observe 
dynamic expression of PR3 gene product in the arthritic joint. 
PR3 is emerging as an important effector of neutrophilic inﬂ am-
mation54 and can cleave, among a variety of substrates, also 
AnxA1.55 Therefore, we concluded this study by testing the 
potential of AnxA1 mimetics, comparing the effect of native 
protein with that of SuperAnxA1, a mutant resistant to serine 
protease-induced cleavage.26 Administered at the dose of 1 μg 
(corresponding to 27 pmol), SuperAnxA1, but not AnxA1, atten-
uated joint disease. It was interesting to note that SuperAnxA1 
did not impact on the induction of arthritis yet it accelerated the 
resolution process so that by day 10 a preserved joint structure 
could be observed. We wish to propose that higher resistance to 
proteolysis might underlie its pharmacological efﬁ cacy, though 
we cannot exclude the confounding element of potential differ-
ences in pharmacokinetics. In any case, these results provide 
strong proof-of-concept that an AnxA1 derivative, resistant to 
proteolysis, could be beneﬁ cial in modulating joint inﬂ amma-
tion. SuperAnxA1 could be the backbone for future strategies 
aiming at capitalising AnxA1 biology for novel antiarthritic 
approaches.
Glucocorticoids are of wide clinical use because of their 
ability to impact several effectors of arthritis, with a recent 
appreciation that, besides inhibition of pro-inﬂ ammatory gene 
expression, gene induction is also of therapeutic relevance.56 
57 In the context of chronic inﬂ ammatory diseases, induction 
of dual-speciﬁ city phosphatase 158 and glucocorticoid-induced 
leucine zipper59 genes could be of mechanistic value. In addi-
tion, we show here that endogenous AnxA1 is also relevant to 
the antiarthritic effect of low-dose Dex, yet we cannot dem-
onstrate induction of this gene at the level of the arthritic joint 
leading to our proposal that the protein is either modulated in 
a non-genomic fashion by this glucocorticoid41 60 or the regula-
tion occurs outside the site of the arthritic joint, an obvious site 
being the vasculature and the control of the egress of blood-
borne neutrophils.4 Analysis of AnxA1 expression in distant 
tissues (eg, blood) during ongoing arthritis and glucocorticoid 
treatment can shed light on this point, which has also been 
touched upon above in relation to lack of correlation between 
joint AnxA1 mRNA and protein expression.
Collectively, this study reveals potent antiarthritic properties 
for Dex in a model of inﬂ ammatory arthritis, using very low 
doses perhaps reminiscent of clinical application on low-dose 
glucocorticoids in RA61 and, in terms of drug discovery pro-
grammes, justiﬁ es the testing of AnxA1 mimetics to control the 
active phase of the disease.
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